Nobel Chemistry Prize Deciphers Life’s Chiral Bias

Wed Oct 07 2026 13:57:46 GMT+0000 (Coordinated Universal Time)

French and Japanese chemists crack the long‑standing mystery of why biomolecules exist only in one mirror‑image form, earning the 2026 Nobel Prize.

The 2026 Nobel Prize in Chemistry honors Henri B. Kagan and Kenso Soai for revealing why living organisms favor one enantiomer of chiral molecules over the other. Their research shows that amino acids, sugars and other key biomolecules exist in two mirror‑image forms, but life uses only one, a question that has puzzled scientists for decades. By demonstrating a chemical mechanism that amplifies a slight initial bias, the scientists provided a plausible origin for biological homochirality. The win confirms the central role of chirality in biology and may spur new advances in synthetic chemistry and drug development. The discovery highlights how basic science can resolve fundamental questions about the nature of life.

Henri Kagan and Kenso Soai win Nobel for solving life’s chiral mystery

The Nobel Committee awarded the Chemistry Prize to French scientist Henri B. Kagan and Japan’s Kenso Soai for solving the chemical mystery of life's asymmetry.

Chiral molecules exist in two mirror‑image forms, known as enantiomers. Life’s biochemical machinery uses only one version—whether of amino acids or sugars—though both are chemically available. The question of why this single-handedness emerged has lingered for decades.

Kagan’s and Soai’s work demonstrated a self‑replicating chemical process that favours one enantiomer over the other, providing a plausible pathway for the natural amplification that could have produced the homochirality of living cells.

Their findings confirm that a simple, non‑biological reaction could generate the subtle imbalance necessary for life’s building blocks to consistently adopt one handedness, a breakthrough that reshapes our understanding of origins of life science.

Beyond theoretical insight, the discovery opens new avenues for designing asymmetric catalysts and precision pharmaceuticals that depend on specific molecular chirality.